查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1821540

2025年全球癌症肿瘤分析市场报告

Cancer Tumor Profiling Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10个工作天内

价格
简介目录

预计未来几年癌症肿瘤分析市场将快速成长，到2029年将达到251.2亿美元，复合年增长率为13.8%。预测期内的增长可归因于免疫疗法和免疫分析在癌症治疗中的应用扩展、液态切片和非侵入性肿瘤分析方法的发展、单细胞测序在更详细地表征肿瘤方面的应用、癌症筛检和早期检测项目的扩展，以及对罕见癌症和罕见癌症亚型分析需求的不断增长。预测期内的主要趋势包括肿瘤分析融入常规临床实践、多体学方法的进展、人工智慧 (AI) 和机器学习在数据分析中的整合、个人化医疗和靶向标靶治疗的开发，以及基因组分析和次世代定序仪(NGS) 技术的进步。

我们预测未来五年的成长率为13.8%，较先前的预测略有下降0.2个百分点。这一下降主要源自于美国与其他国家之间关税的影响。征收关税可能会对美国的精准医疗构成重大挑战，因为这会限制美国从加拿大和瑞典进口的多组体学分析服务和基于人工智慧 (AI) 的肿瘤分析软体，从而可能危及个人化治疗方案。由于互惠关税以及贸易紧张局势和限制措施加剧对全球经济和贸易的负面影响，关税的影响也可能更为广泛。

全球癌症发生率的上升预计将推动癌症和肿瘤分析市场的未来成长。癌症是一种以体内某些细胞不受控制地生长为特征的疾病，这些细胞可能转移到身体的其他部位。随着癌症病例的增加，对肿瘤分析的需求也将增加，因为它有助于医生评估疾病的严重程度。例如，美国专业组织美国癌症协会报告称，2024年美国将新增200万例癌症病例，高于2023年的190万例。因此，全球癌症发生率的上升正在刺激癌症和肿瘤分析市场的成长。

目录

第一章执行摘要

第二章 市场特征

第三章 市场趋势与策略

第四章 市场：宏观经济情景，包括利率、通膨、地缘政治、贸易战和关税，以及新冠疫情和復苏对市场的影响

第五章 全球成长分析与策略分析框架

  • 全球癌症肿瘤分析：PESTEL分析（政治、社会、技术、环境、法律因素、驱动因素与限制因素）
  • 最终用途产业分析
  • 全球癌症肿瘤分析市场：成长率分析
  • 全球癌症肿瘤分析市场表现：规模与成长，2019-2024
  • 全球癌症肿瘤分析市场预测：规模与成长，2024-2029 年，2034 年
  • 全球癌症肿瘤分析：总潜在市场（TAM）

第六章 市场细分

  • 全球癌症肿瘤分析市场（按癌症类型、表现和预测），2019-2024 年、2024-2029 年、2034 年
  • 肺癌
  • 乳癌
  • 大肠直肠癌
  • 摄护腺癌
  • 黑色素瘤
  • 卵巢癌
  • 胃癌
  • 胰臟癌
  • 甲状腺癌
  • 其他类型的癌症
  • 全球癌症肿瘤分析市场：依技术、绩效与预测，2019-2024 年、2024-2029 年、2034 年
  • 次世代定序（NGS）
  • 聚合酵素链锁反应（PCR）
  • 免疫组织化学（IHC）
  • 原位杂交（ISH）
  • 微阵列
  • 其他技术
  • 全球癌症肿瘤分析市场（依流程类型、实际及预测），2019-2024 年、2024-2029 年、2034 年
  • 基因组学
  • 蛋白质体学
  • 表观遗传学
  • 代谢体学
  • 其他类型
  • 全球癌症肿瘤分析市场：依应用、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 个人化医疗
  • 诊断
  • 生物标记发现
  • 预后
  • 调查应用
  • 全球癌症肿瘤分析市场：依肺癌类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 非小细胞肺癌（NSCLC）
  • 小细胞肺癌（SCLC）
  • 全球癌症肿瘤分析市场：乳癌细分（依癌症类型）、实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 荷尔蒙受体阳性
  • 三阴性乳癌
  • HER2阳性乳癌
  • 全球癌症肿瘤分析市场：细分：大肠直肠癌（按癌症类型），实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 大肠直肠癌
  • 直肠癌
  • 全球癌症肿瘤分析市场：前列腺癌类型细分、绩效及预测（2019-2024 年、2024-2029 年及 2034 年）
  • 局部前列腺癌
  • 进行性前列腺癌
  • 全球癌症肿瘤分析市场：恶性黑色素瘤细分（按癌症类型）、实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 皮肤黑色素瘤
  • 非皮肤黑色素瘤
  • 全球癌症肿瘤分析市场：依卵巢癌类型细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 上皮性卵巢癌
  • 非上皮性卵巢癌
  • 全球癌症肿瘤分析市场：依胃癌类型、表现及预测细分，2019-2024 年、2024-2029 年、2034 年
  • 胃腺癌
  • 胃肠道基质肿瘤（GIST）
  • 全球癌症肿瘤分析市场：依癌症类型（胰臟癌）细分，实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 外分泌性胰臟癌
  • 神经内分泌肿瘤
  • 全球癌症肿瘤分析市场：甲状腺癌细分（依癌症类型）、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 甲状腺乳突癌
  • 滤泡性甲状腺癌
  • 甲状腺髓样癌
  • 全球癌症肿瘤分析市场：其他癌症类型细分（按癌症类型），实际及预测，2019-2024 年、2024-2029 年、2034 年
  • 肾癌
  • 膀胱癌
  • 肝癌
  • 食道癌

第七章 区域和国家分析

  • 全球癌症肿瘤分析市场：按地区、绩效及预测，2019-2024 年、2024-2029 年、2034 年
  • 全球癌症肿瘤分析市场：按国家、绩效和预测，2019-2024 年、2024-2029 年、2034 年

第八章 亚太市场

第九章：中国市场

第十章 印度市场

第十一章 日本市场

第十二章：澳洲市场

第十三章 印尼市场

第十四章 韩国市场

第十五章 西欧市场

第十六章英国市场

第十七章：德国市场

第18章：法国市场

第十九章：义大利市场

第20章：西班牙市场

第21章 东欧市场

第22章俄罗斯市场

第23章 北美市场

第24章美国市场

第25章：加拿大市场

第26章 南美洲市场

第27章：巴西市场

第28章 中东市场

第29章：非洲市场

第30章：竞争格局与公司概况

  • 癌症肿瘤分析市场：竞争格局
  • 癌症肿瘤分析市场：公司简介
    • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Caris Life Sciences Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Qiagen Overview, Products and Services, Strategy and Financial Analysis

第31章：其他领先和创新企业

  • Ribomed Biotechnologies Inc.
  • HTG Molecular Diagnostics Inc.
  • NanoString Technologies Inc.
  • NeoGenomics Laboratories Inc.
  • Lucence Health Inc.
  • ACT Genomics Co. LTD
  • Strand Life Sciences
  • IMB Dx Inc.
  • Exact Sciences Corporation
  • Guardant Health
  • Foundation Medicine Inc.
  • Agilent Technologies Inc.
  • Myriad Genetics Inc.
  • Personal Genome Diagnostics Inc.
  • Tempus Labs Inc.

第 32 章全球市场竞争基准化分析与仪表板

第33章 重大併购

第34章近期市场趋势

第 35 章：高潜力市场国家、细分市场与策略

  • 2029年癌症肿瘤分析市场：提供新机会的国家
  • 2029年癌症肿瘤分析市场：细分领域带来新机会
  • 2029年癌症肿瘤分析市场：成长策略
    • 基于市场趋势的策略
    • 竞争对手策略

第36章 附录

简介目录
Product Code: r21188u

Cancer tumor profiling is a laboratory testing method designed to analyze a sample of tumor tissue for specific genes, gene mutations, proteins, or other biomarkers. This comprehensive examination aids in treatment planning and provides valuable insights into the likelihood of cancer recurrence or metastasis.

The primary categories of cancer and tumor profiling encompass lung cancer, breast cancer, colorectal cancer, prostate cancer, melanoma, ovarian cancer, stomach cancer, pancreatic cancer, thyroid cancer, and various other cancer types. Diverse technologies, such as next-generation sequencing (NGS), polymerase chain reaction (PCR), immunohistochemistry (IHC), in situ hybridization (ISH), microarrays, and others, are employed in this process. These technologies cover multiple facets, including genomics, proteomics, epigenetics, metabolomics, and more. Cancer and tumor profiling find applications in personalized medicine, diagnostics, biomarker discovery, prognostics, and research endeavors.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The cancer tumor profiling market research report is one of a series of new reports from The Business Research Company that provides cancer tumor profiling market statistics, including cancer tumor profiling industry global market size, regional shares, competitors with a cancer tumor profiling market share, detailed cancer tumor profiling market segments, market trends and opportunities, and any further data you may need to thrive in the cancer tumor profiling industry. This cancer tumor profiling market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cancer tumor profiling market size has grown rapidly in recent years. It will grow from $13 billion in 2024 to $14.97 billion in 2025 at a compound annual growth rate (CAGR) of 15.1%. The growth in the historic period can be attributed to increasing cancer incidence, growth in precision medicine initiatives and research collaborations, improved cancer diagnostics and early detection methods, availability of a wide range of targeted therapy options, and supportive regulatory frameworks for cancer profiling tests.

The cancer tumor profiling market size is expected to see rapid growth in the next few years. It will grow to $25.12 billion in 2029 at a compound annual growth rate (CAGR) of 13.8%. The growth in the forecast period can be attributed to expansion of immunotherapy and immunoprofiling in cancer treatment, development of liquid biopsy and non-invasive tumor profiling methods, adoption of single-cell sequencing for more detailed tumor characterization, expansion of cancer screening and early detection programs, and increasing demand for rare and orphan cancer subtype profiling. Major trends in the forecast period include integration of tumor profiling into routine clinical practice, advances in multi-omics approaches, integration of artificial intelligence (AI) and machine learning in data analysis, personalized medicine and targeted therapy development, and advances in genomics and next-generation sequencing (ngs) technologies.

The forecast of 13.8% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. The imposition of tariffs may pose a significant challenge for U.S. precision medicine by restricting access to multi-omic profiling services and Artificial intelligence(AI)-based tumor analysis software imported from Canada and Sweden, potentially compromising personalized therapy selection. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising incidence of cancer worldwide is anticipated to drive the growth of the cancer and tumor profiling market in the future. Cancer is a disease characterized by the uncontrolled growth of certain cells in the body, which can spread to other areas. As the number of cancer cases increases, the demand for tumor profiling also rises, as it helps doctors assess the severity of the disease. For example, in 2024, the American Cancer Society, a US-based professional organization, reported that 2 million new cancer cases were diagnosed in the country, an increase from 1.9 million new cases in 2023. Consequently, the increasing incidence of cancer globally is fueling the growth of the cancer and tumor profiling market.

The increasing prevalence of stomach cancer is anticipated to be a key driver for the growth of the cancer and tumor profiling market. Stomach cancer involves the uncontrolled growth of malignant cells in the stomach lining, and cancer and tumor profiling play a crucial role in providing insights into the development of this disease. For example, gastrointestinal stromal tumors (GISTs), though distinct from stomach cancer, can occur in the stomach, and cancer and tumor profiling can help in understanding and treating such cases. As indicated by Cancer Research UK, the incidence of stomach cancer in the UK is expected to decline by 12% between 2023-2025 and 2038-2040. This decline, while positive, highlights the need for continued focus on stomach cancer research and tumor profiling to further address the disease. The growing prevalence of stomach cancer is thus contributing to the expansion of the cancer and tumor profiling market.

Increasing research and development activities are emerging as a significant trend in the cancer and tumor profiling market. Major companies in this sector are prioritizing research and development to meet consumer demands and strengthen their market position. For instance, QIAGEN N.V, a German company specializing in sample and assay technology, recently announced the Conformite Europeenne (CE)-marking and commercialization of the therascreen PIK3CA RGQ PCR Kit in Europe. This diagnostic assay is designed to identify breast cancer patients with PIK3CA mutations, providing crucial information for personalized treatment. The emphasis on research and development activities is a notable trend that is shaping the cancer and tumor profiling market.

In June 2023, Quest Diagnostics, a prominent US-based medical laboratory company, completed the acquisition of Haystack Oncology Inc. for a substantial sum of $450 million. The strategic move by Quest Diagnostics is aimed at broadening access to liquid biopsy technology and strengthening its position in the competitive field of cancer diagnostics. This acquisition is anticipated to augment Quest Diagnostics' research and development capabilities, thereby enhancing its ability to contribute to improved outcomes for cancer patients. Haystack Oncology Inc., based in the United States, is an early-stage oncology company specializing in the development of solid tumor testing technology.

In June 2023, Quest Diagnostics, a US-based medical laboratory firm, acquired Haystack Oncology Inc. for $450 million. This acquisition is intended to broaden access to liquid biopsy technology and enhance Quest Diagnostics' market share in cancer diagnostics by improving research and development capabilities. Haystack Oncology Inc. is a US-based early-stage oncology company focused on developing solid tumor testing technologies aimed at improving outcomes for cancer patients.

Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in cancer and tumor profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the cancer tumor profiling market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The cancer tumor profiling market includes revenues earned by entities by sanger sequencing, pyro sequencing (PyroSeq), chromogenic/ fluorescence in situ hybridization (CISH/FISH) and fragment analysis (FA/Frag. Analysis). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Cancer Tumor Profiling Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on cancer tumor profiling market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for cancer tumor profiling ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cancer tumor profiling market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Cancer Type: Lung Cancer; Breast Cancer; Colorectal Cancer; Prostate Cancer; Melanoma; Ovarian Cancer; Stomach Cancer; Pancreatic Cancer; Thyroid Cancer; Other Cancer Types
  • 2) By Technology: Next-Generation Sequencing (NGS); Polymerase Chain Reaction (PCR); Immunohistochemistry (IHC); In Situ Hybridization (ISH); Microarray; Other Technologies
  • 3) By Process Type: Genomics; Proteomics; Epigenetics; Metabolomics; Other Types
  • 4) By Application: Personalized Medicine; Diagnostics; Biomarker Discovery; Prognostics; Research Applications
  • Subsegments:
  • 1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC); Small Cell Lung Cancer (SCLC)
  • 2) By Breast Cancer: Hormone Receptor-Positive; Triple-Negative Breast Cancer; HER2-Positive Breast Cancer
  • 3) By Colorectal Cancer: Colon Cancer; Rectal Cancer
  • 4) By Prostate Cancer: Localized Prostate Cancer; Advanced Prostate Cancer
  • 5) By Melanoma: Cutaneous Melanoma; Non-Cutaneous Melanoma
  • 6) By Ovarian Cancer: Epithelial Ovarian Cancer; Non-Epithelial Ovarian Cancer
  • 7) By Stomach Cancer: Gastric Adenocarcinoma; Gastrointestinal Stromal Tumors (GISTs)
  • 8) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Neuroendocrine Tumors
  • 9) By Thyroid Cancer: Papillary Thyroid Cancer; Follicular Thyroid Cancer; Medullary Thyroid Cancer
  • 10) By Other Cancer Types: Kidney Cancer; Bladder Cancer; Liver Cancer; Esophageal Cancer
  • Companies Mentioned: F. Hoffmann-La Roche Ltd.; Caris Life Sciences; Thermo Fisher Scientific Inc.; Illumina Inc.; Qiagen; Ribomed Biotechnologies Inc.; HTG Molecular Diagnostics Inc.; NanoString Technologies Inc.; NeoGenomics Laboratories Inc.; Lucence Health Inc.; ACT Genomics Co. LTD; Strand Life Sciences; IMB Dx Inc.; Exact Sciences Corporation; Guardant Health; Foundation Medicine Inc.; Agilent Technologies Inc.; Myriad Genetics Inc.; Personal Genome Diagnostics Inc.; Tempus Labs Inc.; ArcherDX Inc.; Natera Inc.; Bio-Rad Laboratories Inc.; Genetron Health; NantHealth Inc.; Resolution Bioscience; Genomic Testing Cooperative; OncoDNA; Strata Oncology Inc.; Genuity Science; RareCyte Inc.; Inivata Limited; Cepheid
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Cancer Tumor Profiling Market Characteristics

3. Cancer Tumor Profiling Market Trends And Strategies

4. Cancer Tumor Profiling Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Cancer Tumor Profiling Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Cancer Tumor Profiling PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Cancer Tumor Profiling Market Growth Rate Analysis
  • 5.4. Global Cancer Tumor Profiling Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Cancer Tumor Profiling Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Cancer Tumor Profiling Total Addressable Market (TAM)

6. Cancer Tumor Profiling Market Segmentation

  • 6.1. Global Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Melanoma
  • Ovarian Cancer
  • Stomach Cancer
  • Pancreatic Cancer
  • Thyroid Cancer
  • Other Cancer Types
  • 6.2. Global Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In Situ Hybridization (ISH)
  • Microarray
  • Other Technologies
  • 6.3. Global Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Genomics
  • Proteomics
  • Epigenetics
  • Metabolomics
  • Other Types
  • 6.4. Global Cancer Tumor Profiling Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Personalized Medicine
  • Diagnostics
  • Biomarker Discovery
  • Prognostics
  • Research Applications
  • 6.5. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Lung Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Non-Small Cell Lung Cancer (NSCLC)
  • Small Cell Lung Cancer (SCLC)
  • 6.6. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Breast Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hormone Receptor-Positive
  • Triple-Negative Breast Cancer
  • HER2-Positive Breast Cancer
  • 6.7. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Colorectal Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Colon Cancer
  • Rectal Cancer
  • 6.8. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Prostate Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Localized Prostate Cancer
  • Advanced Prostate Cancer
  • 6.9. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Melanoma, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cutaneous Melanoma
  • Non-Cutaneous Melanoma
  • 6.10. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Ovarian Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Epithelial Ovarian Cancer
  • Non-Epithelial Ovarian Cancer
  • 6.11. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Stomach Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Gastric Adenocarcinoma
  • Gastrointestinal Stromal Tumors (GISTs)
  • 6.12. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Pancreatic Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Exocrine Pancreatic Cancer
  • Neuroendocrine Tumors
  • 6.13. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Thyroid Cancer, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Papillary Thyroid Cancer
  • Follicular Thyroid Cancer
  • Medullary Thyroid Cancer
  • 6.14. Global Cancer Tumor Profiling Market, Sub-Segmentation Of Other Cancer Types, By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Kidney Cancer
  • Bladder Cancer
  • Liver Cancer
  • Esophageal Cancer

7. Cancer Tumor Profiling Market Regional And Country Analysis

  • 7.1. Global Cancer Tumor Profiling Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Cancer Tumor Profiling Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Cancer Tumor Profiling Market

  • 8.1. Asia-Pacific Cancer Tumor Profiling Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Cancer Tumor Profiling Market

  • 9.1. China Cancer Tumor Profiling Market Overview
  • 9.2. China Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Cancer Tumor Profiling Market

  • 10.1. India Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Cancer Tumor Profiling Market

  • 11.1. Japan Cancer Tumor Profiling Market Overview
  • 11.2. Japan Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Cancer Tumor Profiling Market

  • 12.1. Australia Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Cancer Tumor Profiling Market

  • 13.1. Indonesia Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Cancer Tumor Profiling Market

  • 14.1. South Korea Cancer Tumor Profiling Market Overview
  • 14.2. South Korea Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Cancer Tumor Profiling Market

  • 15.1. Western Europe Cancer Tumor Profiling Market Overview
  • 15.2. Western Europe Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Cancer Tumor Profiling Market

  • 16.1. UK Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Cancer Tumor Profiling Market

  • 17.1. Germany Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Cancer Tumor Profiling Market

  • 18.1. France Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Cancer Tumor Profiling Market

  • 19.1. Italy Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Cancer Tumor Profiling Market

  • 20.1. Spain Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Cancer Tumor Profiling Market

  • 21.1. Eastern Europe Cancer Tumor Profiling Market Overview
  • 21.2. Eastern Europe Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Cancer Tumor Profiling Market

  • 22.1. Russia Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Cancer Tumor Profiling Market

  • 23.1. North America Cancer Tumor Profiling Market Overview
  • 23.2. North America Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Cancer Tumor Profiling Market

  • 24.1. USA Cancer Tumor Profiling Market Overview
  • 24.2. USA Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Cancer Tumor Profiling Market

  • 25.1. Canada Cancer Tumor Profiling Market Overview
  • 25.2. Canada Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Cancer Tumor Profiling Market

  • 26.1. South America Cancer Tumor Profiling Market Overview
  • 26.2. South America Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Cancer Tumor Profiling Market

  • 27.1. Brazil Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Cancer Tumor Profiling Market

  • 28.1. Middle East Cancer Tumor Profiling Market Overview
  • 28.2. Middle East Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Cancer Tumor Profiling Market

  • 29.1. Africa Cancer Tumor Profiling Market Overview
  • 29.2. Africa Cancer Tumor Profiling Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Cancer Tumor Profiling Market, Segmentation By Technology, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Cancer Tumor Profiling Market, Segmentation By Process Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Cancer Tumor Profiling Market Competitive Landscape And Company Profiles

  • 30.1. Cancer Tumor Profiling Market Competitive Landscape
  • 30.2. Cancer Tumor Profiling Market Company Profiles
    • 30.2.1. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Caris Life Sciences Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Illumina Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Qiagen Overview, Products and Services, Strategy and Financial Analysis

31. Cancer Tumor Profiling Market Other Major And Innovative Companies

  • 31.1. Ribomed Biotechnologies Inc.
  • 31.2. HTG Molecular Diagnostics Inc.
  • 31.3. NanoString Technologies Inc.
  • 31.4. NeoGenomics Laboratories Inc.
  • 31.5. Lucence Health Inc.
  • 31.6. ACT Genomics Co. LTD
  • 31.7. Strand Life Sciences
  • 31.8. IMB Dx Inc.
  • 31.9. Exact Sciences Corporation
  • 31.10. Guardant Health
  • 31.11. Foundation Medicine Inc.
  • 31.12. Agilent Technologies Inc.
  • 31.13. Myriad Genetics Inc.
  • 31.14. Personal Genome Diagnostics Inc.
  • 31.15. Tempus Labs Inc.

32. Global Cancer Tumor Profiling Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Cancer Tumor Profiling Market

34. Recent Developments In The Cancer Tumor Profiling Market

35. Cancer Tumor Profiling Market High Potential Countries, Segments and Strategies

  • 35.1 Cancer Tumor Profiling Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Cancer Tumor Profiling Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Cancer Tumor Profiling Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer